ClinicalTrials.gg
Active, not recruitingNCT04980222Updated Sep 30, 2026Results posted

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of Glofitamab and Tocilizumab in Lymphoma, sponsored by Hoffmann-La Roche. Active, not recruiting at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Posted results revisedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma by Hoffmann-La Roche — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma · Hoffmann-La Roche.

Enrollment
11th of 15
46 · median 96
Started
2022
the only one that year
Phase 2
3 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 15th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 17 studies in Lymphoma by Hoffmann-La Roche is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffuse large B-cell lymphoma (DLBCL), as the first line of treatment.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated patients with CD20-positive DLBCL, including one of the following diagnoses made according to the 2016 World Health Organization (WHO) classification of lymphoid neoplasms

    • DLBCL, not otherwise specified, including GCB and ABC/non-GCB types as well as double-expressor lymphoma (coexpression of MYC and BCL2)
    • High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 translocations
    • Patients with de novo transformed follicular lymphoma (patients with discordant bone marrow involvement, i.e., evidence of low-grade histology in bone marrow) may be considered after discussion with the Medical Monitor
  • (ECOG) Performance Status of 0-2
  • International Prognostic Index (IPI): 2-5
  • of at least 6 months
  • Adequate biomarker blood samples prior to initiation of R-CHOP on Day 1 of Cycle 1 and on Day 1 of Cycle 2 submitted for screening for determination of ctDNA status
  • At least one bi-dimensionally fluorodeoxyglucose (FDG)-avid measurable lymphoma lesion on positron emission tomography/computed tomography (PET/CT) scan
  • (LVEF) >=50%, as determined on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
  • Adequate hematopoietic function
  • use

Additional Inclusion Criterion for ctDNA High-Risk Participants:

  • Plasma sample evaluated to be ctDNA high risk

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma (gray-zone lymphoma), primary mediastinal (thymic) large B-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma (primary or secondary involvement), primary effusion DLBCL, and primary cutaneous DLBCL
  • to any of the individual components of R-CHOP, including prior receipt of anthracyclines, history of severe allergic or anaphylactic reactions to murine monoclonal antibodies, or known sensitivity or allergy to murine products
  • Prior treatment for indolent lymphoma
  • Prior solid organ or stem cell transplant
  • Prior therapy for DLBCL and high-grade B-cell lymphoma (HGBCL) with the exception of palliative, short-term treatment with
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 12 months after the final dose of R-CHOP, 3 months after the final dose of tocilizumab (if applicable), or 2 months after the final dose of glofitamab
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Glofitamab + R-CHOP Immunochemotherapy

    Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days) Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)

    Drug: Glofitamab · Drug: Tocilizumab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Rituximab · Drug: Cyclophosphamide

Interventions

  • Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.

  • Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).

  • Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.

  • Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.

  • Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.

  • Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.

  • Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. End of Treatment Complete Response (EOT CR) Rate

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Overall Response Rate (ORR) at the EOT

    Time frame: Up to approximately 24 months

  2. Progression-free Survival (PFS)

    Time frame: Up to approximately 24 months

  3. Overall Survival (OS)

    Time frame: Up to approximately 24 months

  4. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to 90 days after the final dose of study treatment

  5. Serum Concentration of Glofitamab

    Time frame: At pre-defined intervals up to approximately 10 months

  6. Maximum Concentration (Cmax) of Glofitamab

    Time frame: At pre-defined intervals up to approximately 10 months

  7. Total Exposure (AUC) of Glofitamab

    Time frame: At pre-defined intervals up to approximately 10 months

07

Results

Posted Aug 18, 2026

Participant flow

Participant flow — Overall Study
MilestoneGlofitamab + R-CHOP Immunochemotherapy
Started45
Completed0
Not completed45
Withdrew: Study ongoing41
Withdrew: Death1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryEnd of Treatment Complete Response (EOT CR) Rate
Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of participants
End of Treatment Complete Response (EOT CR) Rate
Percentage of participantsGlofitamab + R-CHOP Immunochemotherapy
End of Treatment Complete Response (EOT CR) Rate73.3 (58.06 to 85.40)
SecondaryOverall Response Rate (ORR) at the EOT
Time frame:
Up to approximately 24 months

Results for this outcome have not been posted.

SecondaryProgression-free Survival (PFS)
Time frame:
Up to approximately 24 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
Up to approximately 24 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Up to 90 days after the final dose of study treatment

Results for this outcome have not been posted.

SecondarySerum Concentration of Glofitamab
Time frame:
At pre-defined intervals up to approximately 10 months

Results for this outcome have not been posted.

SecondaryMaximum Concentration (Cmax) of Glofitamab
Time frame:
At pre-defined intervals up to approximately 10 months

Results for this outcome have not been posted.

SecondaryTotal Exposure (AUC) of Glofitamab
Time frame:
At pre-defined intervals up to approximately 10 months

Results for this outcome have not been posted.

Adverse events

Collected over Approximately 43 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glofitamab + R-CHOP Immunochemotherapy1/45 (2.2%)20/45 (44.4%)40/45 (88.9%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGlofitamab + R-CHOP Immunochemotherapy
Cytokine release syndromeImmune system disorders9/45
NeutropeniaBlood and lymphatic system disorders3/45
AnaemiaBlood and lymphatic system disorders1/45
Febrile neutropeniaBlood and lymphatic system disorders1/45
ThrombocytopeniaBlood and lymphatic system disorders1/45
Sinus tachycardiaCardiac disorders1/45
Jejunal perforationGastrointestinal disorders1/45
Large intestinal obstructionGastrointestinal disorders1/45
PyrexiaGeneral disorders1/45
InfectionInfections and infestations1/45
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGlofitamab + R-CHOP Immunochemotherapy
NeutropeniaBlood and lymphatic system disorders16/45
DiarrhoeaGastrointestinal disorders11/45
Platelet count decreasedInvestigations10/45
AnaemiaBlood and lymphatic system disorders9/45
Neutrophil count decreasedInvestigations9/45
COVID-19Infections and infestations8/45
ThrombocytopeniaBlood and lymphatic system disorders6/45
FatigueGeneral disorders6/45
PyrexiaGeneral disorders6/45
Neuropathy peripheralNervous system disorders6/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Glofitamab + R-CHOP Immunochemotherapy
Median64.0 (39 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Glofitamab + R-CHOP Immunochemotherapy
Female15
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Glofitamab + R-CHOP Immunochemotherapy
Hispanic or Latino4
Not Hispanic or Latino29
Unknown or Not Reported12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Glofitamab + R-CHOP Immunochemotherapy
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American1
White32
More than one race0
Unknown or Not Reported10
08

Study locations

20 sites
09

References and documents

Publications

  • Camus V, Krzisch D, Bruscaggin A, Leveque E, Viennot M, Fornecker LM, Cheminant M, Bailly S, Morschhauser F, Feugier P, Choquet S, Durot E, Carras S, Delette C, Damaj GL, Waultier-Rascalou A, Lebreton P, Le Du K, Galtier J, Houot R, Morineau N, Laribi K, Lebras L, Oberic L, Amorim S, Bocchetta S, Viailly PJ, Rainville V, Ruminy P, Caillot M, Terzi di Bergamo L, Piffaretti D, Pirosa MC, Salehi M, Forestieri G, Drieux F, Veresezan EL, Traverse-Glehen A, Donzel M, Burel L, Bohers E, Lanic MD, Penther D, Becker S, Decazes P, Tonnelet D, Draye-Carbonnier S, Tilly H, Jardin F, Rossi D, Sesques P. Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. Blood Adv. 2026 Jul 14;10(13):4455-4467. doi: 10.1182/bloodadvances.2025019108. PubMed 41979332 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Oct 2024, 31 months.

Results were first posted in Aug 2026, 1 year 9 months after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 31 months is below that.

Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Sep 2024 → Oct 2024 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Jul 28, 2021
StartActual
Mar 22, 2022
Primary completionActual
Oct 24, 2024was Sep 2024
CompletionEst.
Oct 15, 2026was Sep 2026
Results first posted
Aug 18, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 30, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (4 Spain, 1 United States)
  • Memorial Sloan Kettering Cancer Center at Westchester · Harrison, United States
  • Hospital Clinic i Provincial de Barcelona · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Univ. 12 de Octubre; Servicio de Hematologia · Madrid, Spain
  • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
Show 5 removed
  • Memorial Sloan Kettering Cancer Center at Westchester · East White Plains, United States
  • Hospital Clinic i Provincial de Barcelona · Barcelona, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Univ. 12 de Octubre; Servicio de Hematologia · Madrid, Spain
  • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
Sep 30, 2026
Primary completion
Sep 24, 2024→Oct 24, 2024
Sep 30, 2026
Study completion
Sep 30, 2026→Oct 15, 2026
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Posted results revised
    5 sites added, 5 sites removed
    Show 5 added (4 Spain, 1 United States)
    • Memorial Sloan Kettering Cancer Center at Westchester · Harrison, United States
    • Hospital Clinic i Provincial de Barcelona · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Univ. 12 de Octubre; Servicio de Hematologia · Madrid, Spain
    • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
    Show 5 removed
    • Memorial Sloan Kettering Cancer Center at Westchester · East White Plains, United States
    • Hospital Clinic i Provincial de Barcelona · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Univ. 12 de Octubre; Servicio de Hematologia · Madrid, Spain
    • Hospital Clinico Universitario de Salamanca · Salamanca, Spain
    Primary completion Sep 24, 2024→Oct 24, 2024
    Study completion Sep 30, 2026→Oct 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04980222
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Mar 22, 2022
Primary completion
Oct 24, 2024
Completion
Oct 15, 2026 (estimated)
Results posted
Aug 18, 2026
Last update
Sep 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glofitamab

Start the discussion